Summary
In a significant market movement during August 2023, Compass Pathways was the subject of a vc funding. The transaction achieved a gross valuation of £223,280,505. Leading the round was RA Capital, Paradigm BioCapital Advisors, Logos Capital, TCGX, Aisling Capital, PFM Health Sciences, Soleus Capital, Surveyor Capital, Armistice Capital, Vivo Capital, Laurion Capital Management.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
RA Capital
Lead Investor / Acquirer
Paradigm BioCapital Advisors
Lead Investor / Acquirer
Logos Capital
Lead Investor / Acquirer
TCGX
Lead Investor / Acquirer
Aisling Capital
Lead Investor / Acquirer
PFM Health Sciences
Lead Investor / Acquirer
Soleus Capital
Lead Investor / Acquirer
Surveyor Capital
Lead Investor / Acquirer
Armistice Capital
Lead Investor / Acquirer
Vivo Capital
Lead Investor / Acquirer
Laurion Capital Management
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in